Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

GLUE stock hub

Monte Rosa Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

GLUEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.6B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

GLUE

In the news

Latest news · GLUE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-32.6

P25 -105.6P50 -46.5P75 -3.1

ROIC-21.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All GLUE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

189

Groups with data

Currency

USD

Showing 189 of 189 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001826457
Company name	Monte Rosa Therapeutics, Inc.
Country	United States
Country code	US
Cusip	61225M102
Employees	150
Employees Change	16%
Employees Change Percent	11.94
Enterprise value	$1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-06-24
Isin	US61225M1027
Last refreshed	2026-05-10
Market cap	$1.6B
Market cap category	Small-Cap
Price	$19.39
Price currency	USD
Rev Per Employee	286,353.33x
Sector	Healthcare
Sic	2836
Symbol	GLUE
Website	https://www.monterosatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-7.94%
EV Sales Forward	24.38x
EV/Sales	23.54x
P/B ratio	3.13x
P/S ratio	38.14x
PS Forward	39.51x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-238.93%
Gross Profit	$-102.6M
Net Income	$-130M
Net Income Growth Years	2%
Pretax Margin	-307.04%
Profit Per Employee	$-866,760
ROA	-16.41
Roa5y	-18.15
ROCE	-22.28
ROE	-32.62
Roe5y	-37.72
ROIC	-21.11

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	404.19%
Cagr3y	55.25%
EPS Growth Years	2
Revenue Growth	-73.07x
Revenue Growth Q	-95.04x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.08
Assets	$736.4M
Cash	$666.2M
Current Assets	$677.5M
Current Liabilities	$71M
Debt	$39.1M
Debt Equity	$0.07
Equity	$521.9M
Liabilities	$214.5M
Long Term Assets	$58.9M
Long Term Liabilities	$143.5M
Net Cash	$627.2M
Net Cash By Market Cap	$38.29
Net Cash Growth	120.67%
Net Debt Equity	$-1.2
Tangible Book Value	$521.9M
Tangible Book Value Per Share	$6.19
WACC	12.88

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.54
Net Working Capital	$-55.2M
Quick ratio	9.44
Working Capital	$606.5M
Working Capital Turnover	$0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5.92%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	403.64%
200-day SMA	13.95
3Y total return	274.32%
50-day SMA	17.78
50-day SMA vs 200-day SMA	50over200
All Time High	45.56
All Time High Change	-57.44%
All Time High Date	2021-09-07
All Time Low	2.44
All Time Low Change	694.67%
All Time Low Date	2023-10-25
ATR	1.08
Beta	1.62
Beta1y	1.68
Beta2y	1.75
Ch YTD	23.66
High	20.11
High52	25.77
High52 Date	2026-01-08
High52ch	-24.76%
Low	19.16
Low52	3.51
Low52 Date	2025-05-15
Low52ch	452.42%
Ma50ch	9.08%
Premarket Change Percent	1.97
Premarket Price	$20.2
Premarket Volume	1,023
Price vs 200-day SMA	38.98%
RSI	53.94
RSI Monthly	66.52
RSI Weekly	58.95
Sharpe ratio	2.11x
Sortino ratio	4.97
Total Return	-5.92%
Tr YTD	23.66
Tr1m	13.26%
Tr1w	3.14%
Tr3m	-0.82%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	2
Analyst Price Target Top	$29.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.36
Earnings Revenue Estimate	13,446,568x
Earnings Revenue Estimate Growth	-84.17x
Operating Income	$-148.3M
Operating margin	-345.2
Price target	$32
Price Target Change	$65.03
Price Target Change Top	$52.14

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	61,574,686%
Float Percent	72.89%
Shares Insiders	0.57%
Shares Institutions	59.9%
Shares Out	84,479,418
Shares Qo Q	-1.43%
Shares Yo Y	5.92%
Short Float	25.72%
Short Ratio	12.23
Short Shares	18.75

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	807,162.85x
Bv Per Share	6.19
Ch1m	13.26
Ch1w	3.14
Ch1y	403.6
Ch3m	-0.82
Ch3y	274.3
Ch6m	57.51
Change	-2.12%
Change From Open	-1.37
Close	19.81
Days Gap	-0.76
Depreciation Amortization	8,397,000
Dollar Volume	10,608,113.9
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-148.3M
EBITDA	$-139.9M
EPS	$-1.54
F Score	1
Fiscal Year End	December
Founded	2,019
Income Tax	$-1.9M
Ipr	2.05
Iprfo	-11.86
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-17
Ma150	16.81
Ma150ch	15.34%
Ma20	19.34
Ma20ch	0.24%
Next Earnings Date	2026-08-06
Open	19.66
Optionable	Yes
Position In Range	24.21
Post Close	19.39
Postmarket Change Percent	-1.75
Postmarket Price	$19.05
Ppne	53,102,000
Pre Close	19.81
Price Date	2026-05-08
Ptbv Ratio	3.14
Relative Volume	0.68x
Revenue	42,953,000x
Tax By Revenue	-4.35x
Tr6m	57.51%
Us State	Massachusetts
Volume	547,092
Z Score	1.45

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does GLUE pay a dividend?

Capital-return profile for this ticker.

Performance

GLUE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns GLUE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+59.9%

Float: +72.9% of shares outstanding

Insider ownership

+0.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

GLUE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.9

Neutral momentum band

Price vs 200-day MA

+39.0%

50/200-day relationship not available

Beta (5Y)

1.62

More volatile than the market

Sharpe ratio

2.11

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About GLUE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current GLUE stock rating?

Monte Rosa Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GLUE analysis?

The full report lives at /stocks/GLUE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for GLUE?

The latest report frames GLUE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the GLUE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.